The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

Dendritic cell (DC) vaccines induce specific immune responses that can selectively
eliminate target cells. In recent years, many studies have been conducted to explore DC …

The quest for treatment-free remission (TFR) and deep molecular response (DMR) in
chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors …

Relapse is a major problem in acute myeloid leukemia (AML) and adversely affects survival.
In this phase 2 study, we investigated the effect of vaccination with dendritic cells (DCs) …

Peptide-based anticancer vaccination aims at stimulating an immune response against one
or multiple tumor-associated antigens (TAAs) following immunization with purified …

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the most established and
commonly used cellular immunotherapy in cancer care. It is the most potent anti-leukemic …

Abstract A National Cancer Institute consensus study on prioritization of cancer antigens
ranked the Wilms tumor 1 (WT1) protein as the top immunotherapy target in cancer. We …

Immunotherapy has revolutionized therapy in both solid and liquid malignancies. The ability
to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an …

We developed a personalized cancer vaccine in which patient-derived acute myeloid
leukemia (AML) cells are fused with autologous dendritic cells, generating a hybridoma that …

The advent of cancer immunotherapy has revolutionized the field of cancer treatment and
offers cancer patients new hope. Although this therapy has proved highly successful for …